GRAIL LLC is a biotechnology company. It focuses on developing technologies for early cancer detection. GRAIL LLC is based in Menlo Park, United States.
| Revenue (Most Recent Fiscal Year) | $125.60M |
| Net Income (Most Recent Fiscal Year) | $-2.03B |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 9.16 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.53 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 1.18 |
| Pre-Tax Margin (Trailing 12 Months) | -445.82% |
| Net Margin (Trailing 12 Months) | -329.86% |
| Return on Equity (Trailing 12 Months) | -16.64% |
| Return on Assets (Trailing 12 Months) | -14.02% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.23 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.23 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $64.21 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.18 |
| Earnings per Share (Most Recent Fiscal Year) | $-19.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-13.11 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 36.05M |
| Free Float | 35.38M |
| Market Capitalization | $1.23B |
| Average Volume (Last 20 Days) | 0.78M |
| Beta (Past 60 Months) | 3.26 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.85% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |